Abbott Laboratories (NYSE:ABT) Shares Bought by TD Private Client Wealth LLC

TD Private Client Wealth LLC increased its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 7.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,170 shares of the healthcare product maker's stock after purchasing an additional 2,780 shares during the period. TD Private Client Wealth LLC's holdings in Abbott Laboratories were worth $5,594,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of ABT. Brighton Jones LLC lifted its stake in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after acquiring an additional 4,755 shares during the period. Bank Pictet & Cie Europe AG lifted its stake in Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after acquiring an additional 2,774 shares during the period. Proficio Capital Partners LLC lifted its stake in Abbott Laboratories by 99.5% during the 4th quarter. Proficio Capital Partners LLC now owns 8,896 shares of the healthcare product maker's stock valued at $1,006,000 after acquiring an additional 4,437 shares during the period. Andra AP fonden lifted its stake in Abbott Laboratories by 19.8% during the 4th quarter. Andra AP fonden now owns 83,408 shares of the healthcare product maker's stock valued at $9,434,000 after acquiring an additional 13,800 shares during the period. Finally, Banco Santander S.A. lifted its stake in Abbott Laboratories by 155.1% during the 4th quarter. Banco Santander S.A. now owns 27,786 shares of the healthcare product maker's stock valued at $3,143,000 after acquiring an additional 16,893 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $133.70 on Monday. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23. The firm has a market cap of $232.61 billion, a PE ratio of 17.34, a PEG ratio of 2.55 and a beta of 0.73. The firm has a fifty day moving average of $133.29 and a 200 day moving average of $128.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.27 and a current ratio of 1.78.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.89% and a return on equity of 19.01%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.38 billion. As a group, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be issued a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.77%. The ex-dividend date is Tuesday, July 15th. Abbott Laboratories's payout ratio is 30.61%.

Analyst Upgrades and Downgrades

ABT has been the subject of several research reports. Royal Bank Of Canada lifted their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research note on Thursday, April 17th. Stifel Nicolaus boosted their target price on shares of Abbott Laboratories from $135.00 to $145.00 and gave the company a "buy" rating in a research note on Thursday, April 17th. Piper Sandler reiterated an "overweight" rating and issued a $145.00 target price (up from $133.00) on shares of Abbott Laboratories in a research note on Thursday, April 17th. Leerink Partners started coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price for the company. Finally, Bank of America boosted their target price on shares of Abbott Laboratories from $133.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Six investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $142.61.

Insider Activity

In other news, Director Sally E. Blount sold 2,600 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the transaction, the director owned 34,058 shares of the company's stock, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.46% of the stock is owned by insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.